Pediatric Clinical Trials Market Size, Share & Trends Report

Pediatric Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase III), By Study Design (Treatment Studies, Observational Studies), By Indication, By Region, And Segment Forecasts, 2025 - 2030

Report ID: GVR-4-68039-940-1
Number of Report Pages: 120
Format: PDF

Historical Range: 2018 - 2024
Forecast Period: 2025 - 2030
Industry: Healthcare

Market Segmentation

Pediatric Clinical Trials Phase Outlook (Revenue in USD Million, 2018 - 2030)
- Phase I
- Phase II
- Phase III
- Phase IV
Pediatric Clinical Trials Study Design Outlook (Revenue in USD Million, 2018 - 2030)
- Treatment Studies
- Observational Studies
Pediatric Clinical Trials Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Infectious Diseases
- Oncology
- Autoimmune/inflammation
- Respiratory Disorders
- Mental Health Disorders
- Others
Pediatric Clinical Trials Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Phase Outlook (Revenue in USD Million, 2018 - 2030)
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - North America Study Design Outlook (Revenue in USD Million, 2018 - 2030)
    - Treatment Studies
    - Observational Studies
  - North America Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Oncology
    - Autoimmune/inflammation
    - Respiratory Disorders
    - Mental Health Disorders
    - Others
  - U.S.
    - U.S. Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - U.S. Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - U.S. Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Canada
    - Canada Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Canada Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Canada Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Mexico
    - Mexico Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Mexico Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Mexico Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
- Europe
  - Europe Phase Outlook (Revenue in USD Million, 2018 - 2030)
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - Europe Study Design Outlook (Revenue in USD Million, 2018 - 2030)
    - Treatment Studies
    - Observational Studies
  - Europe Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Oncology
    - Autoimmune/inflammation
    - Respiratory Disorders
    - Mental Health Disorders
    - Others
  - UK
    - UK Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - UK Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - UK Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Germany
    - Germany Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Germany Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Germany Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - France
    - France Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - France Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - France Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Italy
    - Italy Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Italy Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Italy Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Spain
    - Spain Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Spain Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Spain Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Denmark
    - Denmark Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Denmark Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Denmark Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Sweden
    - Sweden Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Sweden Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Sweden Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Norway
    - Norway Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Norway Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Norway Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
- Asia Pacific
  - Asia Pacific Phase Outlook (Revenue in USD Million, 2018 - 2030)
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - Asia Pacific Study Design Outlook (Revenue in USD Million, 2018 - 2030)
    - Treatment Studies
    - Observational Studies
  - Asia Pacific Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Oncology
    - Autoimmune/inflammation
    - Respiratory Disorders
    - Mental Health Disorders
    - Others
  - Japan
    - Japan Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Japan Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Japan Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - China
    - China Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - China Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - China Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - India
    - India Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - India Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - India Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Australia
    - Australia Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Australia Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Australia Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - South Korea
    - South Korea Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - South Korea Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - South Korea Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Thailand
    - Thailand Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Thailand Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Thailand Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
- Latin America
  - Latin America Phase Outlook (Revenue in USD Million, 2018 - 2030)
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - Latin America Study Design Outlook (Revenue in USD Million, 2018 - 2030)
    - Treatment Studies
    - Observational Studies
  - Latin America Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Oncology
    - Autoimmune/inflammation
    - Respiratory Disorders
    - Mental Health Disorders
    - Others
  - Brazil
    - Brazil Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Brazil Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Brazil Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Argentina
    - Argentina Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Argentina Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Argentina Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
- MEA
  - MEA Phase Outlook (Revenue in USD Million, 2018 - 2030)
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - MEA Study Design Outlook (Revenue in USD Million, 2018 - 2030)
    - Treatment Studies
    - Observational Studies
  - MEA Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Oncology
    - Autoimmune/inflammation
    - Respiratory Disorders
    - Mental Health Disorders
    - Others
  - South Africa
    - South Africa Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - South Africa Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - South Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Saudi Arabia
    - Saudi Arabia Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Saudi Arabia Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Saudi Arabia Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - UAE
    - UAE Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - UAE Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - UAE Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others
  - Kuwait
    - Kuwait Phase Outlook (Revenue in USD Million, 2018 - 2030)
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Kuwait Study Design Outlook (Revenue in USD Million, 2018 - 2030)
      - Treatment Studies
      - Observational Studies
    - Kuwait Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Oncology
      - Autoimmune/inflammation
      - Respiratory Disorders
      - Mental Health Disorders
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.